A Response From The Authors Of The Health Impact Fund 03/10/2011 by Intellectual Property Watch Leave a Comment In reaction to the recent IP-Watch Inside Views post “Health Impact Fund – Raising Issues of Distribution, IP Rights and Alliances,” by Sakiko Fukuda-Parr and Proochista Ariana, the authors offer a response on behalf of Incentives for Global Health (IGH), the non-profit organization that is developing the Health Impact Fund (HIF) proposal.
Clear The Way For SMEs: Lessons From Nairobi 30/09/2011 by Intellectual Property Watch Leave a Comment Penye nia, pana njia. A Swahili proverb for “when there’s a will, there’s a way,” this might well be the motto for innovative entrepreneurs the world over. Whether they’re based in Nairobi, Brussels or Silicon Valley, what matters the most to entrepreneurs is the success of their businesses. Of course, what’s “in the way” of that success can vary considerably, writes Jonathan Zuck.
Talk Of Treaties, Revenue Increase, Development As WIPO Annual Assemblies Kick Off 27/09/2011 by Rachel Marusak Hermann and William New, Intellectual Property Watch 1 Comment The annual World Intellectual Property Organization meeting of member states kicked off yesterday with hope among participants that the next year could bring a return to positive revenues, a settling of internal dissension, and some of the first treaties at the UN agency in nearly 20 years.
Health Impact Fund – Raising Issues Of Distribution, IP Rights And Alliances 26/09/2011 by Intellectual Property Watch 1 Comment This piece raises several issues with the public health financing proposal called the Health Impact Fund. It questions the relative distribution of costs and benefits; the persistent issue of intellectual property rights; as well as a lack of alliance with existing efforts to increase innovation of and access to essential medicines for the poor.
Questions Arise Over UN Policy On Non-Communicable Diseases And IP Rights 16/09/2011 by William New, Intellectual Property Watch 2 Comments United Nations members this month are setting the future course for global action against a rising public health problem well-known in developed countries and spreading to developing countries: noncommunicable diseases. But whether they will – or should – address concerns that intellectual property rights issues might interfere with access to treatments for such diseases as diabetes, cancer, or heart disease remains to be seen.
Experts Still Divided On Influence Of IP On Biodiversity Conservation 15/09/2011 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment While the global loss of biodiversity is widely recognised, the question of whether the influence of intellectual property rights on the protection of biodiversity is positive or negative does not achieve such consensus. A discussion among specialists on 14 September showed that clear evidence is lacking about the impact of IP rights. Some said the IP system as it stands might be ill-fitted to answer the needs of this particular field.
At WTO, US Takes A Jab At India’s IP Trade Policy 15/09/2011 by William New, Intellectual Property Watch 4 Comments The United States today took a swipe at India’s intellectual property rights policies and enforcement, asserting that it is out of sync with international practices but stopping short of suggesting that its 2005 IP law is out of compliance with World Trade Organization rules.
South Africa Conference On IP And Innovation 14/09/2011 by Intellectual Property Watch 1 Comment A conference being held in South Africa this week will address the sensitive topic of intellectual property and innovation in the developing country context. On hand will be a top team of developed country experts with a mix of Indian and Chinese specialists.
USTR White Paper On Trade In Medicines Raises Questions 14/09/2011 by William New, Intellectual Property Watch 2 Comments The Office of the US Trade Representative this week released a position paper on medicines and trade, in the midst of a controversial negotiation for a trade agreement with Pacific-bordering nations. The USTR “white paper” was billed as trade goals to enhance access to medicines, but stirred sharp criticism from public interest groups which found its claims of promoting medicines access for the poor disingenuous.
Pharma Executive To Head Gates’ Global Health Program 14/09/2011 by William New, Intellectual Property Watch 1 Comment The Bill & Melinda Gates Foundation today announced that Trevor Mundel has been named president of the foundation’s Global Health Program. Mundel is global head of development for Novartis Pharma in Basel, Switzerland and will start at Gates on 1 December.